Publicaciones en colaboración con investigadores/as de Novartis (Sweden) (4)

2024

  1. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

    Lung Cancer, Vol. 197

2022

  1. EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)

    Future oncology (London, England), Vol. 18, Núm. 31, pp. 3481-3492

2019

  1. Effectiveness of dabrafenib in the treatment of patients with braf v600-mutated metastatic melanoma in a named patient program

    Melanoma Research, Vol. 29, Núm. 5, pp. 527-532

2013

  1. Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2

    Clinical Breast Cancer, Vol. 13, Núm. 6, pp. 421-432.e8